TVRD · Tvardi Therapeutics, Inc. · Executive Compensation
$1.08
-0.02 (-1.82%)
At close · Oct 8
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$14.67M
Shares
13.34M
Volume · Oct 8
160.04K
Avg daily vol (3M)
533.47K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Christopher Posner | President and Chief Executive Officer | $2,922,469 |
| Joana Goncalves | former Chief Medical Officer | $1,273,996 |
| Ryan Maynard | Chief Financial Officer | $1,243,857 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Christopher Posner | President and Chief Executive Officer | $2,509,979 |
| Ryan Maynard | Chief Financial Officer | $1,889,302 |
| Joana Goncalves | former Chief Medical Officer | $1,550,355 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Derek Chalmers | Ph.D., D.Sc. Former President and Chief Executive Officer | $10,196,785 |
| Christopher Posner | President and Chief Executive Officer | $9,901,376 |
| Frédérique Menzaghi | Chief Scientific Officer and Senior | $1,737,111 |
| Joana Goncalves | Chief Medical Officer | $1,736,943 |
| Scott M. Terrillion | General Counsel, Secretary and Chief Compliance Officer | $1,585,958 |
| Thomas Reilly | Chief Financial Officer | $810,003 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Derek Chalmers | Ph.D., D.Sc. Former President and Chief Executive Officer | $2,913,609 |
| Thomas Reilly | Chief Financial Officer | $1,588,458 |
| Frédérique Menzaghi | Chief Scientific Officer and Senior | $1,391,310 |
| Joana Goncalves | Chief Medical Officer | $1,338,702 |
| Scott M. Terrillion | General Counsel, Secretary and Chief Compliance Officer | $1,193,681 |
| Richard Makara | VP, Head of Accounting and Controller | $742,968 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Derek Chalmers | Ph.D., D.Sc. Former President and Chief Executive Officer | $3,433,617 |
| Frédérique Menzaghi | Chief Scientific Officer and Senior | $2,226,631 |
| Scott M. Terrillion | General Counsel, Secretary and Chief Compliance Officer | $1,385,433 |
| Mani Mohindru | Former Chief Financial Officer and Chief Strategy Officer | $1,297,266 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Derek Chalmers | Ph.D., D.Sc. President and Chief Executive Officer | $2,789,046 |
| Frédérique Menzaghi | Chief Scientific Officer and Senior Vice President, Research and Development | $1,238,227 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Shaheen Wirk | a member of the Board of Directors | Resigned | 2025-07-14 |
| Stephen O'Brien | Vice President, Finance and Corporate Controller (Principal Accounting Officer) | Appointed | 2025-04-15 |
| Jeffrey Larson | Senior Vice President, Research & Development | Appointed | 2025-04-15 |
| Yixin "Joseph" Chen | Vice President, Chemistry, Manufacturing and Controls | Appointed | 2025-04-15 |
| John Kauh | Chief Medical Officer | Appointed | 2025-04-15 |
| Imran Alibhai | Chief Executive Officer | Appointed | 2025-04-15 |
| Dan Conn | Chief Financial Officer | Appointed | 2025-04-15 |
| Scott Terrillion | General Counsel, Secretary and Chief Compliance Officer | Terminated | 2025-04-15 |
| Christopher Posner | President and Chief Executive Officer | Terminated | 2025-04-15 |
| Ryan Maynard | Chief Financial Officer | Terminated | 2025-04-15 |
| Sujal Shah | Chair of our board of directors | Appointed | 2025-04-15 |
| Shaheen Wirk | Class III director | Appointed | 2025-04-15 |
| Wallace Hall | Class III director | Appointed | 2025-04-15 |
| Cynthia Smith | Class II director | Appointed | 2025-04-15 |
| Sujal Shah | Class II director | Appointed | 2025-04-15 |
| Michael Wyzga | Class I director | Appointed | 2025-04-15 |
| Imran Alibhai | Class II director | Appointed | 2025-04-15 |
| Susan Shiff | Class I director | Appointed | 2025-04-15 |
| Lisa von Moltke | director | Resigned | 2025-04-15 |
| Jeffrey Ives | director | Resigned | 2025-04-15 |
| Helen M. Boudreau | director | Resigned | 2025-04-15 |
| Christopher Posner | director | Resigned | 2025-04-15 |
| Martin Vogelbaum | director | Resigned | 2025-04-15 |
| Dr. Joana Goncalves | Chief Medical Officer | Resigned | 2024-03-22 |
| Helen M. Boudreau | member of the Board | Appointed | 2023-08-03 |